Yesenia Kuan, MD
Psychiatry · Coral Gables, FLNPI 1477057602
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 38.4% of the total. Reporting peaked in 2021 at $677 and has fallen 96.8% since, to $22 in 2025.
Across 27 payments — averaging $44.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$466
- Neurocrine Biosciences, Inc.$311
- Alkermes, Inc.$249
- Johnson & Johnson$125
- Otsuka America Pharmaceutical, Inc.$22
- Luye Pharma (USA) Ltd.$22
- plus $19 from 1 others
Across 392 payments — averaging $5410.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.3M
- Janssen Research & Development, LLC$479K
- Teva Pharmaceuticals USA, Inc.$320K
- E.r. Squibb & Sons, L.L.C.$50K
What the payments were for
- Food & beverage$1,213100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $466 |
| Neurocrine Biosciences, Inc. | 3 | $311 |
| Alkermes, Inc. | 7 | $249 |
| Johnson & Johnson | 3 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,213 in reported general payments places this provider in the 65th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 24 | $476 |
| Escitalopram Oxalate | 45 | $432 |
| Duloxetine Hcl | 24 | $414 |
| Lorazepam | 22 | $230 |
| Quetiapine Fumarate | 21 | $227 |
| Buspirone Hcl | 29 | $220 |
| Temazepam | 15 | $194 |
| Clonazepam | 31 | $176 |
| Trazodone Hcl | 14 | $126 |
| Bupropion XlBupropion Hcl | 13 | $96 |
| Zolpidem Tartrate | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Coral Gables
- Ilan MelnickCoral Gables$2.8M
- Moraima TrujilloCoral Gables$121K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.